Contact
Please use this form to send email to PR contact of this press release:
Biomed Industries, Inc. Advances First-of-Its-Kind Oral NA-931 and Semaglutide Combination Therapy for Treating Obesity
TO:
Michael Willis
Biomed Industries, Inc.
+1 800-824-5135